The aim of the present study was to stratify the risk of detecting a pathogenic copy number variants (CNVs) by array comparative genomic hybridisation (aCGH) in relation to the first trimester Nuchal Translucency (NT) value. Methods: All women who underwent an invasive prenatal sampling for aCGH between 2008 and March 2017 were retrieved from the hospital database. Cases with genomic imbalances > 5MB were excluded because of their detectability by conventional karyotype. The first trimester NT values of the study population were reviewed and expressed in Multiple of Median (MoM) related to the Crown-rump length of the fetus. Maternal age, CRL measurement and NT values were compared between cases with and without aCGH anomaly. The incidence of aCGH anomalies in 5 sub-groups of NT value: ≥4; 3.0-3.9; 2.0-2.9; 1.0-1.9 and ≤1 MoM was evaluated. Additionally, Odds Ratio (OR) for a CGH anomaly was calculated for the foetuses with NT≥2 MoM compared to those <2MoM. Results: Over a 9-years period, a total of 2335 women received array CGH in our institution for different indications (structural ultrasound anomalies, positive screening for Trisomy 21, history of chromosomal anomaly). The overall incidence of pathogenetic CNVs was 4.9%. No differences were found in the distribution of maternal age and CRL measurement between women with or without aCGH anomaly, while NT values were statistically higher in the group with aCGH anomaly. The incidence of pathogenic CNVs among the different NT sub-groups was 9,0%, 7,5% 7,1% 4,7% 4,4% respectively (p=0.03). The OR for having a pathogenic CNVs in presence of NT values ≥2 MoM was 1.7 (95%CI 1,06-2,79; p=0.03) respect to NT values < 2 MoM.
Objectives:
To evaluate the impact of using high-resolution chromosomal microarray (CMA) as the standard diagnostic approach to examine for genomic imbalances in pregnancies with increased risk (≥1 in 300) defined through combined first trimester screening (cFTS). Methods: A retrospective cohort of 575 consecutive pregnancies that had cFTS risk >1:300 through a publicly funded population based screening program in the Central and Northern Regions of Denmark between September 2015 and September 2016. Women with an NT ≥3.5mm, fetal malformation or opting for NIPT were excluded. Comparative genomic hybridisation was performed using a 180K oligonucleotide array on DNA extracted directly from samples. Genomic outcomes are reported in relation to cFTS findings. Results: 22 cases (22/575, 3.8%; 95% CI: 2.5-5.7%) of Trisomy 13, 18 and 21 were detected. A further 14 cases (14/575, 2.4%; 95% CI: 1.4-4.0%) of other types of aneuploidy were detected as well as 15 (15/575, 2.6%: 95% CI: 1.5-4.3%) cases with a pathogenic or likely pathogenic copy number variants (CNV). Reducing the cFTS risk threshold for invasive diagnostic testing to 1 in 100 or 1 in 50 would have led, respectively, to 60% or 100% of the pathogenic CNVs being missed. Conclusions: CMA is a valuable diagnostic technique that can identify an increased number of genomic aberrations in pregnancies at increased risk after cFTS. Limiting diagnostic testing to pregnancies with a risk above 1:100 or 1:50, as proposed in contingent NIPT/invasive testing models, will lead to a significant proportion of pathogenic CNVs being missed at first trimester screening.
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Implications of inconclusive results in prenatal maternal serum cell-free DNA testing Objectives: To investigate the pregnancy outcomes in a cohort of women who failed to obtain a result from non-invasive prenatal testing (NIPT). Methods: This is a retrospective cohort study conducted at a multicentre private practice between March 2013 and June 2016 comparing women who failed to obtain a result from NIPT to the general obstetric population. Maternal demographic characteristics and all relevant antenatal investigations were collated for the participants and pregnancy outcomes were obtained by phone interview. Results: During the study period, 131 of 12033 women (1.1%) failed to return a NIPT result. We obtained the outcomes of 98 patients of these 131 women (74%). Of these 98 patients, 85 pregnancies resulted in a live birth, whereas 13 cases resulted in pregnancy loss. The overall cohort was of significantly increased weight and age compared to the general Australian obstetric population and were at significant increased risk of chromosomal aneuploidies (8% vs. 0.2%, p<0.0001). The 85 pregnancies resulting in a live birth were complicated by significantly higher rates of pre-eclampsia (16% vs. 1.5%, p<0.0001) and gestational diabetes (22% vs. 7.5%, p<0.0001). Rates of preterm delivery (11% vs. 8.5%, p=0.4) and IUGR (12% vs. 10%, p=0.5) were not significantly different. Fetal loss between 12 and 25 weeks occurred in 7 cases (5%). The chromosome abnormalities were Trisomies 21, 13, 10 (mosaic), 9, X plus triploidy (x2) and XXY. Although not significant, compared to those with NIPT result success, antenatal investigations demonstrated decreased FbhCG MoM (0.96 vs. 1.1, p=0.12) and PAPP-A MoM (0.8 vs. 0.93, p=0.01) and increased mean uterine artery PI (1.96 vs. 1.44, p=0.0006) indicating higher rates of smaller and dysfunctional placenta. Conclusions: This study demonstrated that women who fail to obtain a result from NIPT are at increased risk of adverse pregnancy outcome, in particular chromosomal aneuploidy (9%), gestational diabetes (27%) and pre-eclampsia (11%). This has important implications for counselling, further investigation and clinical management.
